Our approach combines deep scientific knowledge with business acumen, helping you navigate the complex journey from discovery to clinic with greater confidence and efficiency.
We partner with founders and executive leaders to develop straetgic roadmaps that transform academic discoveries into clinically tested therapeutics - optimizing your funding and accelerating the path to profitability.
Comprehensive services designed to unlock your organization's full potential through strategic planning, operational excellence, and visionary leadership.
A Vision Executor is a trusted team member who implements near-term strategy for long-term successs. As Vision Executor, I partner with you to define, plan and execute a transformational journey to move from present state to future state. We develop a comprehensive and step by step vision and execute together in a timebound manner.
BS in Chemsitry, University of the Ozarks
PhD in Biochemistry, University of Delaware
Postdoctoral Training, Drexel University
Just call me your right hand gal. I am a scientist by training, a highly collaborative person, and a vision caster who loves to turn an idea into an actionable plan.
During my time in academia, I was drawn to translational research. I saw the value in combining the expertise of academia and industry to accelerate developement of scientific breakthroughs into usable therapies for patients, saving time and money. I quickly moved into that environment and managed a $50M gene therapy research portfolio at University of Pennsylvania's Gene Therapy Program that formed the basis for several spin out companies before spinning myself out to an early stage start up Cabaletta Bio. As Director of Operations, I managed research, manufacturing, regulatory submissions and product development planning for multiple cell therapy assets and successfully submitted 2 more INDs. I spent 3 years on the investment team at Fore site Capital Management, a venture capital firm that invests in therapeutics and healthcare companies, doing clinical landscape analysis and capital planning for a subset of the $4b portfolio.
This unique combination of scientific knowledge and business experience allows me to understand both the technical challenges of therapeutic development and the strategic requirements for business success in the biotech ecosystem.